GRAIL, Inc. - Common Stock (GRAL)

The company's stock received a favorable assessment from a Wall Street analyst this week.

The multi-cancer early detection (MCED) company delivered some extremely bad news to investors in February, but the stock may attract risk tolerant investors now.

The market took a more positive view on the company's prospects today, and there's still an opportunity, however small, for the Galleri trial to prove out.

A large clinical trial of the company's cancer screening test did not produce the desired result.

The company continues to come under pressure after a very disappointing trial result.

GRAIL develops advanced cancer detection technologies, serving healthcare providers and individuals seeking early diagnostic solutions.

The top-line results from its landmark trial were not good, but there's more data to come, and it might prove more favorable for investors.

Baird analyst Catherine Ramsey Schulte slashed the price target on Grail to $82 from $113 while reiterating an ‘Outperform’ rating.

GRAIL (NASDAQ: GRAL) shares plunged after the NHS-Galleri trial failed to meet its primary endpoint. Explore the trial results.

Data from Stocktwits indicated retail sentiment on QQQ turned bearish amid elevated message volume.

The trial did not show a statistically significant reduction in Stage III-IV cancer diagnoses, the company said.

Investors are getting excited by the prospects for Grail's Galleri test in 2026.

In a resounding vote of confidence for the future of multi-cancer early detection (MCED), Canaccord Genuity reiterated its "Buy" rating for GRAIL (Nasdaq: GRAL) on Tuesday, January 13, 2026, setting an ambitious price target of $105.00. The move comes as the liquid biopsy pioneer reported preliminary full-year 2025 financial

A combination of operational improvements and developments at its key rival bolstered the stock recently.

The company has significant potential with its comprehensive cancer test.

GRAIL (GRAL) Q3 2025 Earnings Call Transcript